Tesamorelin
Tesamorelin is a growth hormone releasing hormone analog that has been shown toincrease lGF-1 levels in men by an average of 181 micrograms/liter. lt binds andstimulates human GHRH receptors with similar potency as endogenous GHRH. lt has ahost of other benefits including nootropic effects and reducing triglycerides. Tesamorelinresearch has subsequently been shown to decrease carotid intima media thickness(clMT), visceral adipose tissue (VAT), and C-reactive proteins (CRP) in a recent study. lthas not been shown to significantly affect other pituitary hormones and their respectivemechanisms in the body. Additionally, studies have shown it to improve cognitive functionfor healthy older adults and also for people with mild cognitive impairment who are at anincreased risk of progressing to Alzheimer’s disease.
Ipamorelin
Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist. The potency ofghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties.However, unlike other GH-Secretagogues this pentapeptide doesn’t release the samevolumes of cortisol, acetylcholine, prolactin and aldosterone. lt is for this reasonlpamorelin has been considered the first selective GH-Secretagogue.
By combining both ipamorelin and tesamorelin, it may be possible to produce enhancedeffects because each peptide stimulates the growth hormone axis via two different mechanisms. Together, they both work synergistically to stimulate the pituitary gland toproduce and secrete your own natural arowth hormone at more vouthful levels, Researchhas shown that the net effect of combining both of these peptides results in better deepsleep, reduced triglycerides, VAT, and clMT, improved cognition, and overall bettermetabolic function.
lpamorelin and Tesamorelin exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale tohumans. lpamorelin and Tesamorelin are for sale at PEPTIDE GURUS is limited toeducational and scientific research only, not for human consumption. Only buy lpamorelinand Tesamorelin if you are a licensed researcher.
Article Author
The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. ELogan holds a doctorate degree from Case Western Reserve University School ofMedicine and a B.S. in molecular biology.
Scientific JournaAuthor
David E. Beck, MD, co-author of“Prospective, randomized, controlled, proof-of-conceptstudy of the Ghrelin mimetic ipamorelin for the management of postoperative ileus inbowel resection patients” specializes in colon and rectal surgery.
David E. Beck, MD is being referenced as one of the leading scientists involved in there search and development of lpamorelin. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, recognize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. DavidE. Beck, MD is listed in [4 ]under the referenced citations.
ReferencedCitations
1.Adrian, S., et al. (2019).The Growth Hormone Releasing Hormone Analogue,Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIVJ Frailty Aging, 8(3):154-159.DO1: 10.14283/jfa.2018.45.
2.Clemmons, D.R., Miller, S.,& Mamputu, J.(2017). Safety and Metabolic Effects ofTesamorelin, A Growth Hormone-releasing Factor Analogue, in Patients with Type2 Diabetes: A Randomized, Placebo-controlled Trial. PLoS One, 12(6):e0179538DOl:10.1371/journal.pone.0179538.
3.Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M,Orskov H.lpamorelin, a new growth-hormone-releasing peptide, induceslongitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi.10.1054/ghir.1999.9998.PMID: 10373343.
4.Beck, David E., et al. “Prospective, Randomized, Controlled, Proof-of-ConceptStudy of the Ghrelin Mimetic lpamorelin for the Management of Postoperative lleusin Bowel Resection Patients.” International Journal ofColorectal Disease, vol. 29no.12,21 0ct.2014,pp.1527-1534,10.1007/s00384-014-2030-8
5.Michael Ankersen, Nils L. Johansen, Kjeld Madsen, Birgit S. Hansen, KirstenRaun, Karin Kramer Nielsen, Henning Thggersen, Thomas K. Hansen, BerndPeschke, Jesper Lau, Behrend F. Lundt, and Peter H. Andersen. A New Series ofHighly Potent Growth Hormone-Releasing Peptides Derived fromlpamorelin.Journal of Medicinal Chemistry 1998 41 (19),3699-3704. DO1:10.1021/im9801962.
6.Raun, Kirsten & Hansen, B & Johansen, N & Thøgersen, Henning & Madsen, K &Ankersen, Michael & Hongaard Andersen, Peter. (1998). lpamorelin, the firstselective growth hormone secretagogue.European journal of endocrinology /European Federation of Endocrine Societies.139.552-61.10.1530/eje.0.1390552.
7.Fourman, L.T., et al. (2017). Visceral Fat Reduction with Tesamorelin is Associatedwith lmproved Liver Enzymes in HIV. AIDS, 31(16):2253-2259.DO1:10.1097/0AD.0000000000001614.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
